Cost effectiveness will be the sticking point for pathogen inactivation or reduction technologies for platelets, the Blood 2018 conference has been told. And while systems such as Intercept and Mirasol may be effective against infectious and possibly non-infectious threats such as transfusion-associated graft versus host disease (GVHD), operational gains were unlikely to offset the investment ...
Extra safety for platelets comes at a cost
By Mardi Chapman
26 Oct 2018